0000000000055481

AUTHOR

Federica Papaccio

0000-0002-0302-8696

showing 10 related works from this author

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress

2020

Gastroesophageal adenocarcinoma (GEA) represents a heterogeneous disease and, when diagnosed as locally advanced or metastatic, it is characterized by poor prognosis. During the last few years, several molecular classifications have been proposed to try to personalize treatment for those patients diagnosed with advanced disease. Nevertheless, despite the great effort, precision medicine is still far from being a reality. The improvement in the molecular analysis due to the application of high throughput technologies based on DNA and RNA sequencing has opened a novel scenario leading to the personalization of treatment. The possibility to target epidermal growth factor receptor (HER)2, Claud…

Oncologymedicine.medical_specialtymedicine.medical_treatmentprecision medicinePopulationlcsh:MedicineReviewDisease03 medical and health sciences0302 clinical medicineInternal medicinemedicineEpidermal growth factor receptoreducationadvanced gastric cancer030304 developmental biology0303 health scienceseducation.field_of_studyGastroesophageal adenocarcinomabiologybusiness.industrylcsh:RGeneral MedicineImmunotherapyAdvanced gastric cancerPrecision medicineAdvanced gastric cancer; New drug development; Precision medicineFibroblast growth factor receptor030220 oncology & carcinogenesisbiology.proteinnew drug developmentbusinessJournal of Clinical Medicine
researchProduct

490P Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor

2020

Treatment responseOncologybusiness.industryColorectal cancerGenomic ProfileOrganoidCancer researchMedicineHematologybusinessmedicine.diseaseAnnals of Oncology
researchProduct

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

2018

Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiv…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisDerived neutrophil-to-lymphocyte ratio; Head and neck squamous cell carcinoma; Inflammation-based prognostic scores; Neutrophil-to-lymphocyte ratio; Overall survival; Prognostic factors; Prognostic nutritional indexoverall survivalhead and neck squamous cell carcinomaderived neutrophil-to-lymphocyte ratio03 medical and health sciences0302 clinical medicineneutrophil-to-lymphocyte ratioInternal medicinemedicine1506Stage (cooking)Neutrophil to lymphocyte ratioOriginal ResearchUnivariate analysisbusiness.industryHead and neck cancerInduction chemotherapyprognostic factorsprognostic nutritional indexmedicine.diseaseHead and neck squamous-cell carcinomaClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisinflammation-based prognostic scoresbusinessESMO open
researchProduct

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

2020

BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence.; METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study. ctDNA was tracked to detect minimal residual disease by droplet digital PCR. CDX2 expression was…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerPathological stagingConsensus molecular subtypesPerineural invasionlcsh:RC254-282Circulating Tumor DNAInternal medicinemedicineBiomarkers TumorHumansDigital polymerase chain reactionCDX2 Transcription Factor1506plasma circulating-tumor DNAStage (cooking)Original Researchbusiness.industryInterleukin-6Plasma circulating-tumor DNA.Multimodal therapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisMinimal residual diseaseColon cancerOncologyColonic NeoplasmsCDX2 homeoprotein; colon cancer; consensus molecular subtypes; interleukin-6; plasma circulating-tumor DNANeoplasm Recurrence LocalbusinessCDX2 homeoproteinImmunostaining
researchProduct

Development of a living organoid biobank derived from colorectal cancer patients: Towards personalized medicine

2019

Abstract Background Organoids are 3D in vitroprimary culture of great interest for translational research representing an efficient and reproducible cancer model. The aim of this project is to generate a biobank of colorectal cancer (CRC) patients derived organoids (PDOs) that could be used to analyze molecular characteristics and to test different treatments as well as to study the underlying molecular causes of cancer and treatment resistance. Methods Primary or metastatic CRC tissues have been obtained from patients who underwent surgery. Tissue has been washed and incubated with antibiotics. After mechanical and enzymatic digestion, free cells have been seeded in Matrigel with proper me…

OncologyEnzymatic digestionbusiness.industryMedicineLibrary scienceHematologyTreatment resistancebusinessBiobank
researchProduct

Prognostic nutritional index (PNI) is an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer (LAHNSCC)

2017

Oncologymedicine.medical_specialtyPrognostic factorIndex (economics)business.industryHead and neck cancerCellHematologymedicine.diseaseHead and neck squamous-cell carcinomamedicine.anatomical_structureOncologyInternal medicinemedicinebusinessPrognostic Nutritional Index (PNI)
researchProduct

ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition

2019

Abstract Background Colorectal cancer (CRC) represents a relevant public health problem. The identification of new markers involved in the mechanisms of invasiveness represents a priority in order to better understand cancer development and generate new therapeutic targets. Recently, our group demonstrated overexpression of ZNF518B gene, which encodes an unknown zinc finger transcription factor, in CRC. A transcriptome-wide gene expression profile revealed its implication in different biological processes related to the progression of CRC, especially in the epithelial to mesenchymal transition (EMT). Methods To study the biological processes regulated by ZNF518B, we performed a ClariomS Arr…

HCT116 CellOncologymedicine.medical_specialtyTranscriptional factorColorectal cancerbusiness.industryeducationTranslational researchHematologymedicine.diseaseIn vitro analysisOncologyInternal medicinemedicineCancer developmentEpithelial–mesenchymal transitionbusinessSignalling pathwayshealth care economics and organizationsAnnals of Oncology
researchProduct

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer

2020

Simple Summary The outcome for patients with rectal cancer has significantly improved over the last thirty years. Previously, local relapses in the pelvis occurred in more than one third of all patients with apparently localized tumors. Total mesorectal excision was the first step to improve local control by reducing local relapses to less than 5%. Preoperative radiation, either short-course or long-course with concurrent administration of chemotherapy, was a second important step for reducing local relapses to a minimum, even in locally advanced tumors where a clean surgical resection was not possible or would not be curative. Magnetic resonance imaging is a very useful tool for locoregion…

0301 basic medicineCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentLocally advancedReviewlcsh:RC254-282law.inventionMetastasis03 medical and health sciencesMesorectal fascia0302 clinical medicineRandomized controlled triallawmedicinewatch and wait strategyChemotherapyPreoperative chemoradiotherapyPostoperative chemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-risk locally advanced rectal cancer; Total neoadjuvant treatment; Watch and wait strategyhigh-risk locally advanced rectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisRadiologybusinesstotal neoadjuvant treatmentCancers
researchProduct

The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision

2017

Curative treatment of rectal cancer depends on an optimal surgical resection, with the addition of neoadjuvant radiotherapy (RT) with or without concomitant chemotherapy (ChT) in more advanced tumors. The role of adjuvant ChT is controversial and a more intensified neoadjuvant approach with the addition of ChT before or after RT, or even as single modality, is currently being explored in trials. A systematic review selecting randomised phase II and III trials on the role of ChT in localized rectal cancer was performed. Data show that neoadjuvant ChRT improves locoregional control in resected rectal cancer. Short-course RT (SCRT) could give similar outcomes to ChRT. The addition of oxaliplat…

0301 basic medicineOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAntineoplastic Agents03 medical and health sciences0302 clinical medicineClinical Trials Phase II as TopicPreoperative chemoradiationInternal medicineMedicineCombined Modality TherapyHumansRadiology Nuclear Medicine and imagingRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicChemotherapybusiness.industryRectal NeoplasmsGeneral MedicineAdjuvant chemotherapy; Preoperative chemoradiation; Rectal cancermedicine.diseaseCombined Modality TherapyNeoadjuvant TherapyOxaliplatinAdjuvant chemotherapyRadiation therapy030104 developmental biologyOncologyClinical Trials Phase III as Topic030220 oncology & carcinogenesisConcomitantRadiotherapy AdjuvantbusinessAdjuvantmedicine.drug
researchProduct

488P Patient-derived organoids as a tool for modelling localized colorectal cancer

2020

OncologyColorectal cancerbusiness.industryCancer researchOrganoidmedicineHematologymedicine.diseasebusinessAnnals of Oncology
researchProduct